Skip to main content

Advertisement

Table 1 Characteristics of included RCT studies

From: Ranibizumab for macular edema secondary to retinal vein occlusion: a meta-analysis of dose effects and comparison with no anti-VEGF treatment

Study (year) Center Location Type of RVO Primary endpoint NO. of eyes Age (year) Sex (male/female) Patient characteristics
IVR 0.5 mg IVR 0.3 mg control IVR 0.5 mg IVR 0.3 mg control IVR 0.5 mg IVR 0.3 mg control
CRUISE (2010) M United States (95site) CRVO 6 m 130 132 130 65.4 ± 13.1 69.7 ± 11.6 65.4 ± 13.1 80/50 71/61 72/58 1) Age > 18 y
2) BCVA between 73 and 24 ETDRS letters
3) RVO duration within 12 months
4) CFT ≥ 250 μm
ROCC (2010) M Norway (4 sites) CRVO 6 m 16   16 NA   NA NA   NA 1) Age > 50 y
2) BCVA between 73 and 6 ETDRS letters
3) CFT ≥ 250 μm
BRAVO (2010) M United States (93site) BRVO 6 m 131 134 132 65.2 ± 12.7 66.6 ± 11.2 65.2 ± 12.7 71/60 67/67 74/58 1) Age > 18 y
2) BCVA between 73 to 24 ETDRS letters
3) RVO duration within 12 months
4) CFT ≥ 250 μm
Tan (2014) M Australia (5site) BRVO 12 m 15   21 69.6 ± 11.6   66.7 ± 10.7 8/7   9/12 1) Age > 18 y
2) BCVA between 68 to 20
3) RVO duration between 6 weeks to 9 months.
4) CFT ≥ 250 μm
  1. RCT = prospective randomized controlled; RVO = retinal vein occlusion; IVR = intravitreal ranibizumab; M = multicenter; CRVO = central retinal vein occlusion; BCVA = best-corrected visual acuity; ETDRS = Early Treatment Diabetic Retinopathy Study; CFT = central foveal thickness; NA = not available; BRVO = branch retinal vein occlusion.